Complete report on H2 2016 pipeline review of Anaphylaxis with 17 market data tables and 13 figures, spread across 38 pages is available at http://www.reportsnreports.com/reports/774098-anaphylaxis-pipeline-review-h2-2016.html.
It also reviews key players involved in the therapeutic development for Anaphylaxis and special features on late-stage and discontinued projects.
The report also reviews key players involved in the therapeutic development for Anaphylaxis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Anaphylaxis Pipeline Review, H2 2016 report include Adamis Pharmaceuticals Corp, MannKind Corp and Monosol Rx LLC. Drug profiles discussed in this research report includes epinephrine, ET-523, Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders and Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders.
Order a purchase copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=774098.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Anaphylaxis and reviews pipeline therapeutics for Anaphylaxis by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Anaphylaxis therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Anaphylaxis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Anaphylaxis.
Another newly published market research report titled on Obstructive Sleep Apnea - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Obstructive Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obstructive Sleep Apnea and special features on late-stage and discontinued projects. Companies discussed in this research are Galleon Pharmaceuticals Inc, RespireRx Pharmaceuticals Inc, SK Biopharmaceuticals Co Ltd and Vivus Inc. Obstructive Sleep Apnea Pipeline market research report of 49 pages is available at http://www.reportsnreports.com/reports/774096-obstructive-sleep-apnea-pipeline-review-h2-2016.html.
Explore more reports on Pharmaceuticals
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013